This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Non-small cell lung cancer (NSCLC)

Lysine-specific demethylase 2A
(KDM2A; JHDM1A)

Patient sample, cell culture and mouse studies suggest decreasing levels of KDM2A could help treat NSCLC. In patient NSCLC tumor samples, KDM2A mRNA and protein levels were higher than those in normal lung tissue samples and correlated with poor survival. In NSCLC cell lines expressing high levels of KDM2A, siRNA against KDM2A decreased cell proliferation and invasiveness compared with control siRNA. In mice injected with NSCLC cells with high KDM2A levels, pretreatment with siRNAs against KDM2A led to no lung tumors, whereas control siRNA pretreatment led to multiple lung tumors. Next steps include using lung-specific knockout or transgenic mouse models to provide genetic evidence that KDM2A promotes NSCLC.

SciBX 6(47); doi:10.1038/scibx.2013.1345
Published online Dec. 12, 2013

Patent application filed; available for licensing

Wagner, K.W. et al. J. Clin. Invest.; published online Nov. 8, 2013;
doi:10.1172/JCI68642
Contact: Min Gyu Lee, The University of Texas MD Anderson Cancer Center, Houston, Texas
e-mail:
mglee@mdanderson.org